MedTrace Logo

UC-MSC Transplantation for Left Ventricular Dysfunction After AMI

NCT03902067 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-05-11

No results posted yet for this study

Summary

A pilot study to evaluate the safety and feasibility of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction by catheter transplantation

Conditions

  • Left Ventricular Dysfunction
  • Acute Myocardial Infarction

Interventions

BIOLOGICAL

UC-MSC

0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU， at the concentration of 2x10(7) cells/ml.

BIOLOGICAL

Control Group

Routine treatment without catheter infusion

Sponsors & Collaborators

  • Shanghai Jiao Tong University Affiliated Sixth People's Hospital

    collaborator OTHER

  • Shanghai Life Science & Technology

    lead INDUSTRY

Principal Investigators

  • Chengxing Shen, Dr. · Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03902067 on ClinicalTrials.gov